The global pelvic cancer induced hemorrhagic cystitis market is expected to experience significant growth in the coming decade, reaching a staggering US$11 billion by 2033. This represents a compound annual growth rate (CAGR) of 18.01% from a valuation of US$2.1 billion in 2023, according to a recent market analysis. Hemorrhagic cystitis is a debilitating condition …